Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Peer Review reports

Original Submission
12 Feb 2013	Submitted	Original manuscript
3 Mar 2013	Reviewed	Reviewer Report - Oscar Fernández
12 May 2013	Reviewed	Reviewer Report - Channa Kolb
7 Jul 2013	Author responded	Author comments - Cristina Guijarro-Castro
Resubmission - Version 2
7 Jul 2013	Submitted	Manuscript version 2
Publishing
10 Jul 2013	Editorially accepted
11 Jul 2013	Article published	10.1186/1471-2377-13-82

Back to article page